Risk Factors and Clinical Outcomes in Chronic Coronary
An Analysis of the Randomized, Double-Blind COMPAS

European Journal of Preventive Cardiology

27, 296-307

DOI: 10.1177/2047487319882154

Citation Report

#	Article	IF	Citations
1	Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease: A Subanalysis of the COMPASS Randomized Clinical Trial. JAMA Cardiology, 2021, 6, 21-29.	16.3	89
2	Rivaroxaban for the Prevention of Major Adverse Cardiovascular Events in Patients With Coronary or Peripheral Artery Disease. Future Cardiology, 2020, 16, 597-611.	1.2	2
3	Rivaroxaban: A Review for Secondary CV Prevention in CAD and PAD. Drugs, 2020, 80, 1465-1475.	15.5	13
4	Analysis of Effectiveness, Safety, and Bleeding Related to Rivaroxaban in Elderly Patients. Clinical and Applied Thrombosis/Hemostasis, 2020, 26, 1076029620925923.	2.2	9
5	Combining Anticoagulant and Antiplatelet Therapies for Chronic Atherosclerotic Disease. Circulation, 2020, 141, 1855-1858.	24.6	2
6	Carotid Disease. , 2020, .		0
7	Impact of Smoking on Cardiovascular Outcomes in Patients With Stable Coronary Artery Disease. European Journal of Preventive Cardiology, 2021, 28, 1460-1466.	6.1	40
8	Clinical Use of Impedance Cardiography for Hemodynamic Assessment of Early Cardiovascular Disease and Management of Hypertension. High Blood Pressure and Cardiovascular Prevention, 2020, 27, 203-213.	3.1	26
9	Novel Antithrombotic Regimen in Patients With Ischemic Heart Disease and Peripheral Arterial Disease: Can We Identify Those Who Derive the Highest Benefit?. Journal of Medical Economics, 2020, 23, 670-672.	3.0	0
10	Safety and Efficacy of Rivaroxaban and Apixaban in Patients With Increased Body Mass: A Systematic Review. Clinical Drug Investigation, 2021, 41, 353-369.	3.1	11
11	Life and Limb Protection With Dual Anti-Thrombotic Pathway Inhibition: COMPASS Ushers in a New Day in Atherothrombotic Risk Reduction. Med, 2021, 2, 233-242.	12.3	4
12	Prevalence of Diabetes and Impact on Cardiovascular Events and Mortality in Patients With Chronic Coronary Syndromes, Across Multiple Geographical Regions and Ethnicities. European Journal of Preventive Cardiology, 2022, 28, 1795-1806.	6.1	37
13	Chronic Coronary Syndrome: Overcoming Clinical Practice Guidelines. The Role of the COMPASS Strategy. Current Cardiology Reviews, 2021, 17, 294-305.	2.9	4
14	Peripheral Artery Disease and Clinical Outcomes in Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis. Clinical Cardiology, 2021, 44, 1050-1057.	3.1	13
15	Association of Apolipoprotein Levels With Peripheral Arterial Disease: A Meta-Analysis of Literature Studies. European Journal of Preventive Cardiology, 2022, 28, 1980-1990.	6.1	13
16	Prevalence and Clinical Implications of Eligibility Criteria for Prolonged Dual Antithrombotic Therapy in Patients With PEGASUS and COMPASS Phenotypes: Insights From the START-ANTIPLATELET Registry. International Journal of Cardiology, 2021, 345, 7-13.	3.2	47
17	Coronary Artery Disease With a High Risk of Complications: How to Identify Such Patients and Choose Management Tactics?. Rational Pharmacotherapy in Cardiology, 2020, 16, 465-473.	0.6	0
18	Editorial Comments: Focus on Lipid and Atherosclerosis. European Journal of Preventive Cardiology, 2022, 28, 1975-1977.	6.1	2

#	Article	IF	Citations
19	Impact of Risk Factor Control on Peripheral Artery Disease Outcomes and Health Disparities. Vascular Medicine, 2022, 27, 323-332.	2.3	6
20	Depression Screening in Patients With Vascular Disease. Vascular, 2023, 31, 758-766.	1.1	4
21	Multiple Metabolic Comorbidities and Their Consequences Among Patients With Peripheral Arterial Disease. PLoS ONE, 2022, 17, e0268201.	3.2	14
22	Major Adverse Events in Patients With Peripheral Artery Disease After Endovascular Revascularization: A Retrospective Study. Journal of Clinical Medicine, 2022, 11, 2547.	3.8	9
23	Patients Selected for Dual Pathway Inhibition in Clinical Practice Have Similar Characteristics and Outcomes to Those Included in the COMPASS Randomized Trial: The XATOA Registry. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 825-836.	5.0	29
24	Optimal or Standard Control of Systolic and Diastolic Blood Pressure Across Risk Factor Categories in Patients With Chronic Coronary Syndromes. European Journal of Preventive Cardiology, 2023, 30, 935-947.	6.1	3
25	Smoking and Coronary Artery Disease Risk in Patients With Diabetes: A Mendelian Randomization Study. Frontiers in Immunology, 2023, 14, 891947.	6.9	12
26	Antithrombotic Treatment in Coronary Artery Disease. Current Pharmaceutical Design, 2023, 29, 2764-2779.	3.4	4
27	Risk Factors for Major Adverse Cardiovascular Events After Coronary Artery Bypass Grafting Using Radial Artery Grafts. Frontiers in Cardiovascular Medicine, 2023, 10, 1238161.	3.2	4
28	Acompanhamento de Dois Anos de Pacientes com Cardiopatia Isquêmica Crônica em um Centro Especializado no Brasil. Arquivos Brasileiros De Cardiologia, 2023, 120, e20220440.	1.2	3
29	The Net Clinical Outcome of Dual-Pathway Inhibition in Clinical Practice: The “Xarelto Plus Acetylsalicylic Acid: Treatment Patterns and Outcomes in Patients With Atherosclerosis” Registry. Journal of Clinical Medicine, 2024, 13, 1956.	3.8	5
30	Cost Effectiveness Analysis Rivaroxaban Plus Aspirin Versus Aspirin Alone in Treatment Cardiovascular Diseases: A Systematic Review. Medical Journal of the Islamic Republic of Iran, 2024, 38, 751-760.	0.9	1
31	Clinical Profile, Management and Outcomes of Patients Taking Dual Pathway Inhibition for Cardiovascular Protection in Clinical Practice in Latin America. Data From the XATOA Registry. Drugs in Context, 2026, 15, 1.	2.5	0
32	App-Based Lifestyle Modification After Percutaneous Coronary Intervention: A Multicenter Randomized Controlled Trial. Cardiovascular Intervention and Therapeutics, 2026, 41, 1041-1052.	5.1	0